Value through Innovation

main navigation

jump to contentto meta navigation
Press Releases

page content

jump to main navigationto meta navigation

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back12345678910111213141516
03.02.2012 Boehringer Ingelheim, GWT and the TU Dresden sign diabetes research collaboration
31.01.2012 FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adults with Type 2 Diabetes - For Non-U.S. and Non-UK Media
26.01.2012 Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply
26.01.2012 Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib* - FOR NON-US MEDIA ONLY
14.12.2011 Boehringer Ingelheim significantly expands its supply center for China
09.12.2011 Boehringer Ingelheim completes patient entry for Phase III trial
programme in Hepatitis C - For media outside the U.S.
08.12.2011 Linagliptin demonstrates meaningful improvement in glycaemic control in initial combination therapy with metformin - EX US, UK and UAE Medical Media Only. Under embargo until 08 Dec, 10 am CET
07.12.2011 Winners of the Making More Health Competition Bring Fresh Innovation to Solving Problems in Health
01.12.2011 Boehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab
23.11.2011 Pradaxa® awarded Prix Galien for most innovative product in Canada - For NON-US, Non-Canada and NON-UK Healthcare Media Only
17.11.2011 Boehringer Ingelheim race to the finish line in support of World Diabetes Day - EX US and UK.
14.11.2011 New RE-LY® sub-analyses demonstrate safety and efficacy of Pradaxa® (dabigatran etexilate) in patients with heart failure & those undergoing surgery - For NON-US, NON-Canada and NON-UK Healthcare Media Only
09.11.2011 Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition
08.11.2011 BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients - For media outside of the U.S.A only
07.11.2011 Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment - For media outside of the U.S.A. only
04.11.2011 Boehringer Ingelheim gains approval of extended 4.5 hour time-window for Actilyse® in acute ischaemic stroke for majority of EU countries* - For non-UK and non-US media
01.11.2011 NICE issues Final Appraisal Determination (FAD) with unrestricted recommendation for Pradaxa® (dabigatran etexilate) for patients with non-valvular atrial fibrillation - For NON-US, UK & Canada Media Only
27.10.2011 Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe - For European Health Media Only
back12345678910111213141516
back to top

Media Contact

Media Contact
Our media contacts

News & Press Releases

News

Other News & Press Releases